Colon-targeted adsorbent may SHIELD gut microbiome from antibiotic disruption
23 Nov 2020
byAudrey Abella
DAV132, a novel, first-in-class, colon-targeted adsorbent capable of adsorbing a wide range of antibiotics, was well-tolerated in hospitalized elderly patients receiving oral/parenteral fluoroquinolones* (FQs), and protected the intestinal microbiota without influencing the plasma concentration of free FQs, the phase II European SHIELD trial has shown.